Beijing Tide Pharmaceutical Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer and myelofibrosis.
Beijing Double-Crane Runchuang Technology Co. Ltd. has disclosed protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
New protein arginine N-methyltransferase 5 (PRMT5) inhibitors are detailed in a Scinnohub Pharmaceutical Co. Ltd. patent and described as potentially useful for the treatment of cancer.
Scientists at Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Chengdu Chipscreen Pharmaceutical Ltd. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Asieris Pharmaceuticals Co. Ltd. has synthesized new protein arginine N-methyltransferase 5 (PRMT5) inhibitors described as potentially useful for the treatment of bladder cancer.
Shanghai Allist Pharmaceuticals Co. Ltd. has synthesized protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Adenoid cystic carcinoma (ACC) is a rare malignancy of the secretory glands with a high tendency to invade adjacent tissue and spread to the lung, bone or liver. No treatments other than surgery or radiotherapy are available, so new therapeutic strategies are urgently needed.
